# IONpath

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ionpath

- Industry: Healthcare
- Headquarters: Menlo Park, US
- Website: www.ionpath.com
- Total disclosed funding: $18M
- Latest round: Series B (Jul 8, 2020)
- Investors on record: 8

## About

IONpath, Inc. is a biotechnology research company focused on spatial omics solutions, utilizing proprietary technology for advanced molecular imaging to enhance biomarker discovery in cancer research and drug development.IONpath, Inc., founded in 2014 and headquartered in Menlo Park, US, specializes in advanced spatial omics solutions. The company has not undergone any significant pivots or changes in its business strategy. It operates independently without mention of any parent or subsidiary companies. The firm has raised a total of USD 18.00 mn from multiple rounds, with the most recent funding being a SERIES B round led by Samsara BioCapital on May 11, 2022, and has a current valuation of USD 69.109 mn. The leadership includes CEOs Paul Davy and Sander Gubbens. IONpath has engaged in 4 deals to date with backing from notable investors including Bruker Corporation and Genoa Ventures.IONpath, Inc. specializes in advanced spatial omics solutions, offering proprietary technology that facilitates high-throughput molecular imaging. This capability enables researchers to visualize and quantify biomolecules in their native tissue architecture, ultimately aiding in biomarker discovery and understanding complex biological systems. The company primarily serves academic institutions, pharmaceutical companies, and clinical research organizations in North America and Europe, delivering essential tools for precision medicine and personalized therapeutic approaches.IONpath's revenue model is centered on B2B transactions with research institutions and pharmaceutical companies for its spatial omics platforms. Revenue is generated through the sale of instrument systems, consumable reagents, and related services, which include direct sales and service contracts for ongoing support. Collaborations with key research entities play a significant role in validating their technology's application, with a pricing structure reflecting the advanced capabilities provided to high-end research facilities.IONpath, Inc. plans to leverage its recent funding round from May 2022 to support the development of new products and services within the spatial omics space. Specific upcoming offerings are currently under design but details on release dates are not available. The company is focused on expanding into new markets, particularly in Europe and Asia, aiming for this expansion to occur by the end of 2023. Recent funding will also support initiatives to enhance their existing product lines and bolster R&D efforts, reflecting their commitment to advancing research capabilities.

## Funding rounds

- Series B, Jul 8, 2020, $18M — Norwich Ventures, Bruker Corporation, Vertical Venture Partners, Genoa Ventures, Paladin Partners, Samsara BioCapital, Trancos Ventures, NDCapital
- Series A, Jan 20, 2018 — Genoa Ventures
- Seed, Oct 1, 2015 — Genoa Ventures

## Investors

- Genoa Ventures (https://capitalatlas.ai/funds/genoa-ventures) — Seed, Series A, Series B
- Norwich Ventures (https://capitalatlas.ai/funds/norwich-ventures) — Series B
- Bruker Corporation — Series B
- Vertical Venture Partners (https://capitalatlas.ai/funds/vertical-venture-partners) — Series B
- Paladin Partners — Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B
- Trancos Ventures (https://capitalatlas.ai/funds/trancos-ventures) — Series B
- NDCapital (https://capitalatlas.ai/funds/ndcapital) — Series B